Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Payables (2019 - 2025)

Biodesix (BDSX) has disclosed Payables for 7 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 39.32% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Dec 2025, up 39.32%, and an annual FY2025 reading of $3.1 million, up 39.32% over the prior year.
  • Payables was $3.1 million for Q4 2025 at Biodesix, down from $3.6 million in the prior quarter.
  • Across five years, Payables topped out at $16.4 million in Q3 2022 and bottomed at $1.6 million in Q1 2023.
  • Average Payables over 5 years is $4.1 million, with a median of $3.0 million recorded in 2023.
  • The sharpest move saw Payables crashed 94.62% in 2021, then surged 914.44% in 2022.
  • Year by year, Payables stood at $1.7 million in 2021, then grew by 3.15% to $1.7 million in 2022, then skyrocketed by 71.86% to $3.0 million in 2023, then fell by 25.67% to $2.2 million in 2024, then soared by 39.32% to $3.1 million in 2025.
  • Business Quant data shows Payables for BDSX at $3.1 million in Q4 2025, $3.6 million in Q3 2025, and $3.0 million in Q2 2025.